Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- Conditions
- Anemia; Non-dialysis Dependent Chronic Kidney Disease
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 304
- Registration Number
- NCT03329196
- Locations
- 🇯🇵
Research site, Yamanashi, Japan
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- AnemiaDialysis-Dependent Chronic Kidney Disease
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Akebia Therapeutics
- Registration Number
- NCT03242967
- Locations
- 🇺🇸
Research Site, Northridge, California, United States
Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration
- Conditions
- Perinatal StrokePAISNeonatal Stroke
- Interventions
- Drug: Saline
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 80
- Registration Number
- NCT03171818
- Locations
- 🇳🇱
Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
- Conditions
- NeurocognitiveNeonatalNeuroprotectiveNeurodevelopmental Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- NICHD Neonatal Research Network
- Target Recruit Count
- 650
- Registration Number
- NCT03169881
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
EPO-4-Rhesus Study
- Conditions
- Erythroblastosis, FetalErythroblastosis Fetalis, Rh DiseaseErythroblastosis Fetalis Due to RH AntibodiesErythroblastosis Fetalis Due to Isoimmunization
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
- Target Recruit Count
- 42
- Registration Number
- NCT03104426
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Mild Encephalopathy in the Newborn Treated With Darbepoetin
- Conditions
- Neonatal EncephalopathyHypoxic-Ischemic Encephalopathy Mild
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 28
- Registration Number
- NCT03071861
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT03029208
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.
- Conditions
- Chronic Kidney DiseaseCardiovascular Diseases
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 29
- Registration Number
- NCT02987465
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
- Conditions
- Anaemia
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 271
- Registration Number
- NCT02969655
- Locations
- 🇯🇵
GSK Investigational Site, Yamaguchi, Japan
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
- Conditions
- Hemodialysis Chronic Kidney Disease Patients With Anemia
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 303
- Registration Number
- NCT02952092
- Locations
- 🇯🇵
Site JP00033, Aichi, Japan
🇯🇵Site JP00004, Ehime, Japan
🇯🇵Site JP00041, Ibaraki, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.